Fecal Microbiota Transplantation (FMT) & Metabolic diseases / Metabolic disorders

Fecal Microbiota Transplantation (FMT) For For Metabolic diseases / Metabolic disorders: Rationale and proposed mechanisms

Fecal Microbiota Transplantation (FMT) is being studied as a way to test whether changing the gut microbiome can change metabolism. The rationale is that gut microbes may help drive metabolic problems, rather than merely accompany them. Transferring a whole microbial community could alter microbial products and signals - such as butyrate production and bile-acid metabolism - that may influence insulin sensitivity and inflammation (3).
Obesity-related metabolic disorders are associated with changes in the gut microbiota. A healthier microbial community might affect weight and glucose regulation, with the hoped-for benefit of improved insulin sensitivity or blood-sugar control. Proposed pathways include short-chain fatty acids influencing GLP-1 and satiety, and changes in bile-acid metabolism affecting lipid processing (2).

Fecal Microbiota Transplantation (FMT) For Metabolic diseases / Metabolic disorders: Evidence from clinical studies and reviews

Early studies and broad interpretation
Overall, the evidence reviewed by Hanssen et al. (1) suggests that fecal microbiota transplantation (FMT) may influence metabolic disease, but effects are inconsistent and context-dependent:

• Some studies found temporary improvements in insulin sensitivity in metabolic syndrome.


• A small type 1 diabetes trial suggested preservation of beta-cell function after repeated autologous FMT.


• Studies in non-alcoholic fatty liver disease reported preliminary changes without establishing clinical benefit.
  Pemberton (2024) reviews FMT as a potential treatment for obesity, type 2 diabetes, and non-alcoholic fatty liver disease. The article proposes that FMT may influence metabolism through changes in gut microbes, insulin sensitivity, inflammation, gut-barrier function, short-chain fatty acids, bile acids, and GLP-1. It describes animal and early human findings as suggestive but mixed, with especially limited evidence for fatty liver disease and unclear long-term effects on weight. This is an editorial/review, not a clinical trial or meta-analysis, and establishes no pooled estimates. Infection risks, donor screening, and variable responses remain concerns. Overall, FMT is presented as promising but investigational, requiring larger, longer-term trials before routine use (4).
  Before-and-after evidence without control groups
  A meta-analysis of six single-arm studies involving 130 participants, published up to October 2022, found that weight, BMI, HOMA-IR, and HbA1c decreased after FMT. Fasting glucose showed no significant overall change after sensitivity analysis, and fasting insulin did not change significantly. Although the diabetes subgroup showed lower fasting glucose, that finding came from a single study. Because these pooled results came from before-and-after comparisons without control groups and the evidence base was small, they suggest a possible metabolic benefit but do not establish that FMT caused the changes or demonstrate that it is an effective alternative to bariatric surgery. Larger, controlled clinical studies are needed (2).
  Hu et al. (2) describe FMT as a therapy for weight loss and glycemic control, and as helping prevent and treat metabolic issues associated with obesity. They suggest it may offer an alternative for patients who prefer not to undergo bariatric surgery. This is a proposed interpretation of the limited evidence, not an established clinical role: the before-and-after evidence above does not establish causation or show that FMT is an effective alternative to bariatric surgery (2).

Fecal Microbiota Transplantation (FMT) For Metabolic diseases / Metabolic disorders: Randomized-trial evidence

Li et al. (2023): This systematic review and meta-analysis included 10 randomized trials and 334 participants. Participants were adults with overweight or obesity; conditions such as metabolic syndrome, type 2 diabetes, hypertension, dyslipidemia, and fatty liver were allowed. The review assessed healthy-donor FMT, given by oral capsules or duodenal tube, against control treatments. Follow-up ranged from 2 to 26 weeks. Anthropometric measures did not significantly improve, so the clearest finding was not weight loss. Some metabolic markers - HOMA-IR, fasting insulin, blood pressure, lipids, and CRP - shifted in a potentially favorable direction, but fasting glucose rose slightly and HbA1c did not significantly improve. The authors emphasized the small total sample and called for more high-quality trials (5).
Zhang et al. (2025): This systematic review and meta-analysis included 11 randomized trials involving 320 overweight or obese adults with metabolic disorders. In the primary analyses, FMT did not significantly improve BMI, HOMA-IR, HbA1c, or lipid measures, although BMI and HOMA-IR showed non significant trends toward improvement. The BMI result became statistically significant under one alternative analysis assumption. The authors considered the overall evidence uncertain and low-certainty, highlighted differences in donor selection and treatment protocols, and called for better-standardized trials (7).
Savytska et al. (2026): This review of randomized trials of FMT for metabolic disorders - including type 2 diabetes, obesity, metabolic syndrome, and insulin resistance - covered six trials and 120 participants. FMT did not significantly improve HOMA-IR. Evidence for HbA1c and clamp-measured insulin sensitivity was sparse or inconclusive, and certainty was low or very low overall. The authors concluded that current evidence does not support routine FMT for metabolic conditions and recommended use only in clinical trials pending larger, better-standardized studies (6).

Fecal Microbiota Transplantation (FMT) For Metabolic diseases / Metabolic disorders: Interpretation, limitations, and safety

Across the evidence, findings are inconsistent and context-dependent. Some studies report short-term changes in insulin sensitivity or metabolic markers, but results do not establish consistent, clinically meaningful weight loss or glycemic benefit. Current evidence suggests modest, short-term improvements in insulin sensitivity and markers of glycemia, without consistent, clinically meaningful weight loss (1, 4).
FMT transfers a complex mixture of microbes and non-microbial components. Outcomes may depend on donor and recipient characteristics, diet, medications, procedures, and microbial engraftment; effects therefore cannot be attributed simply to transferred bacteria or assumed to be uniform. Serious safety risks, including transmission of drug-resistant organisms, and methodological challenges such as blinding and placebo selection further limit interpretation (1). Donor screening, treatment protocols, and responses vary across studies (4, 7).

Fecal Microbiota Transplantation (FMT) For Metabolic diseases / Metabolic disorders: Clinical status and overall conclusion

FMT remains experimental, not a standard therapy for metabolic disorders such as obesity, type 2 diabetes, or metabolic syndrome. The more positive claims of a potential treatment or alternative to bariatric surgery should be read alongside the limitations of the underlying evidence: before-and-after findings do not establish causality, and randomized-trial reviews have found no consistent significant benefit across key outcomes.
FMT is currently viewed primarily as a valuable tool for testing the causal role of the gut microbiome. Wider clinical use would require rigorous donor screening, standardized methods, and larger, well-powered, blinded trials with meaningful clinical outcomes. More targeted microbial therapies may ultimately offer a practical alternative to whole-stool transplantation (1).

References

(1) Hanssen et al. 2021 Cell Metab 33(6):1098-1110
(2) Hu et al. 2023 Life 13: 1488
(3) Vrieze et al. 2012 Gastroenterology 143(4): 913-17
(4) Pemberton 2024 Health Sci J 18(11): 1202
(5) Zecheng et al. 2023 Diabetes Research and Clinical Practice 202: 110803
(6) Savytska et al. 2026 Front Med 13: 1983162
(7) Zhang et al. 2025 Frontiers in Endocrinology 16: 1737543
see also:
Fecal Microbiota Transplantation (FMT) & Adiposity / Obesity
Fecal Microbiota Transplantation (FMT) & Metabolic Syndrome (MetS)
Metabolic diseases / Metabolic disorders & Drugs/Treatments